Core Viewpoint - The company, Nanjing Novogene Bioinformatics Technology Co., Ltd., has announced its expected daily related transactions for 2026, amounting to RMB 14.90 million, which is based on its business needs and the actual transactions from 2025 [3][9]. Group 1: Daily Related Transactions Overview - The expected daily related transactions for 2026 are estimated at RMB 14.90 million, reflecting an increase from the actual transactions of RMB 2.98 million in 2025 [3][9]. - The 2025 daily related transactions were approved by the board and amounted to RMB 5.90 million, with actual transactions being significantly lower than the estimate [1][2]. Group 2: Approval Process - The approval process for the 2026 expected daily related transactions involved multiple meetings, including a review by the audit committee and independent directors, confirming that the transactions are fair and will not harm the company or its shareholders [4][5][6]. - The independent directors unanimously agreed that the expected transactions are necessary for daily operations and will not affect the company's independence or financial health [6][9]. Group 3: Related Parties and Transaction Details - The expected transactions will involve related parties, specifically Nanjing Dino Wei Hua Biotechnology Co., Ltd., and will include sales of products, provision of technical services, and procurement of goods [7][8]. - Pricing for these transactions will be based on market prices, industry practices, and mutual agreement between the parties involved [8]. Group 4: Impact on Company - The expected daily related transactions are deemed necessary for the company's operations and are structured to ensure fairness and mutual benefit, thereby safeguarding the interests of all shareholders [9].

证券代码：688105 证券简称：诺唯赞 公告编号：2026-004 南京诺唯赞生物科技股份有限公司 关于2026年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 1 本次日常关联交易预计事项无需提交股东会审议。 公司本次预计的关联交易与日常经营相关，定价方式公允、合理，在公平、 自愿、平等、互利的基础上开展，不会损害公司和全体股东的利益，不会对 公司持续经营能力、盈利能力及独立性等方面产生不利影响。 重要内容提示： 为规范公司日常关联交易管理，根据相关法律、法规与《公司章程》规定， 南京诺唯赞生物科技股份有限公司（以下简称"公司"）财务部梳理了 2025 年 度日常关联交易实际发生情况，同时根据公司实际业务开展需要对 2026 年度日 常关联交易情况进行预计，具体情况如下： 一、日常关联交易基本情况 （一）2025 年度日常关联交易履行的审议程序 公司于 2024 年 12 月 11 日召开第二届董事会第十四次会议、第二届监事会 第十二次会议，审议通过了《关于增加 2024 年度日常关联交易预计 ...

南京诺唯赞生物科技股份有限公司 第二届董事会独立董事专门会议第六次会议决议 南京诺唯赞生物科技股份有限公司(以下简称"公司"）于 2026 年 2 月 5 日 发出召开第二届董事会独立董事专门会议第六次会议的通知，并于 2026 年 2 月 6 日以邮件通讯表决方式召开。本次会议应出席独立董事 3 名，实际出席独立董 事 3 名。本次会议的召集、召开程序符合《公司章程》《独立董事工作制度》和 有关法律、法规的规定。经全体独立董事审议和表决，会议形成如下决议： 审议通过《关于 2026 年度日常关联交易预计的议案》 公司本次关于 2026 年度日常关联交易的预计是基于公司日常业务开展需要， 在公平、自愿、平等、互利的基础上进行，定价方式平等、合理，不会对公司及 公司财务状况、经营成果产生不利影响，不存在损害公司及全体股东特别是中小 股东利益的情形，公司不会因此对关联人形成依赖，不会对公司的独立性造成影 响。 我们作为公司独立董事，一致同意公司本次 2026 年度日常关联交易预计事 项，并同意将该议案提交公司董事会审议。如有涉及关联董事的，相关关联董事 应在审议上述议案时回避表决。 表决结果：同意 3 票，反对 ...

Group 1 - The company approved a share repurchase plan on June 19, 2025, with a budget between RMB 5 million and RMB 10 million, aiming to buy back part of its issued A-shares at a price not exceeding RMB 30 per share within 12 months [1] Group 2 - As of January 30, 2026, the company has repurchased a total of 127,703 shares, representing 0.03% of the total share capital of 397,734,544 shares, with a total expenditure of RMB 2,999,704.25 [2] Group 3 - The company will adhere to relevant regulations during the repurchase period and will make decisions based on market conditions, ensuring timely disclosure of the progress of the share repurchase [3]

Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

证券代码：688105 证券简称：诺唯赞 公告编号：2026-003 南京诺唯赞生物科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/6/20 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 6 6 月 | 年 | 月 | 19 | 日~2026 | 年 | 18 日 | | 预计回购金额 | 500万元~1,000万元 | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 12.77万股 | | | | | | | | 累计已回购股数占总股本比例 | 0.03% | | | | | | | ...

Core Viewpoint - The company, Nanjing Novogene Biotechnology Co., Ltd., anticipates a net loss for the fiscal year 2025, primarily due to increased VAT rates on biological products and rising sales expenses [2][5]. Group 1: Performance Forecast - The company expects a net profit attributable to shareholders of the parent company to be between -20 million and -10 million yuan for 2025 [2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between -85 million and -70 million yuan [2]. - The financial data in this forecast has not been audited by registered accountants [2]. Group 2: Previous Year Performance - In the same period last year, the total profit was -58.25 million yuan, with a net profit attributable to shareholders of the parent company at -18.09 million yuan [3]. - The net profit after deducting non-recurring gains and losses was -83.22 million yuan [3]. - The earnings per share for the previous year were -0.05 yuan per share [4]. Group 3: Reasons for Performance Changes - The expected loss in 2025 is attributed to the VAT increase from 3% to 13%, adversely affecting overall revenue and profitability [5]. - The company is focusing on enhancing technology and product R&D, optimizing cost reduction and efficiency measures, while maintaining strong market investment and expanding innovative and overseas markets, which has led to increased sales expenses [5]. - The company has made provisions for credit impairment losses and asset impairment losses based on actual circumstances and prudence, which has also negatively impacted the current operating results [5].

Core Viewpoint - The company, Novogene, announced an expected net loss attributable to the parent company of between 20 million to 10 million yuan for the fiscal year 2025 [2] Group 1 - The projected net loss for 2025 is estimated to be between -20 million yuan and -10 million yuan [2]

Core Viewpoint - The company, Novavax (688105.SH), has announced an expected net profit attributable to the parent company for the year 2025 to be between -20 million to -10 million yuan [1] Group 1 - The projected net profit range indicates a potential loss for the company in 2025 [1]

诺唯赞(688105.SH)发布公告，公司预计2025年度实现归属于母公司所有者的净利润-2000万元至-1000万 元。 ...